Rob Phillips Interview with Alan Kohler
The interview with Alan Kohler was focused on the sustainability of our transformational first profit and triple-digit growth, and the foreseeable upside for Uscom China during the Chinese post-viral economic rebound, and the worldwide COVID-19 effect.
Alan was quick to question if our strong Q3 results reflect sustainable revenue from the new distribution model in China or one-off orders from COVID-19 specific installations. While many current Chinese tenders will be granted over the next 12 months and it is expected that the recommendation for the use of USCOM 1A for treatment of severe Coronavirus patients by the Chinese Health and Medical Commission of the People’s Republic of China will impact purchasing decisions of Hospitals and clinicians foreseeably, our underlying revenue growth is underwritten by new distributor contracts with Uscom China. While Uscom has spent the last two years developing its new China operations, the impact of the COVID-19 spread to Europe and the US is now also beginning to impact operations and sales pipelines there also. These matters and more are discussed in the interview.
This presentations allow us to present our progress to investors and potential investors and confirm the accelerating growth trajectory that reflects both our China restructures and the impact of China COVID-19 sales. Still to come are the European and US impacts of COVID-19, and the midterm modernising of ICU’s worldwide to more effectively deal with the impact of seasonal infectious disease outbreaks.
Uscom was founded on the foresight that infections would grow to become a major global medical health focus as increasingly antibiotic-resistant bacteria and more virulent seasonal viruses were spread among increasingly dense global populations. Over the last 15 years, Uscom has developed the most advanced technologies that have been specialized to address these growing challenges and we specialise in non-invasive and accurate cardiovascular and pulmonary devices. We are proud to be developing solutions to save lives and improve the life quality of children, adults and the elderly worldwide and be part of the COVID-19 solution before it even existed.